首页> 外文OA文献 >587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models

【2h】

587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models

机译：587肿瘤活化的FC工程抗CTLA-4单克隆抗体XTX101显示了临床前模型的肿瘤选择性Pd和功效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Kurt Jenkins; Parker Johnson; Minjie Zhang; Wilson Guzman; Ugur Eskiocak; Megan McLaughlin; Caitlin O’Toole; Magali Pederzoli-Ribeil; Miso Park; John Williams; Margaret Karow; Jennifer O’Neil; Timothy Clackson; Ronan O’Hagan;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 587?Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models [J] . Kurt Jenkins, Parker Johnson, Minjie Zhang, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：587？肿瘤活化的FC工程化抗CTLA-4单克隆抗体XTX101，显示临床前模型的肿瘤选择性PD和功效
2. A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models [J] . Willingham Stephen B., Ho Po Y., Hotson Andrew, Cancer immunology research. . 2018,第10期

机译：A2AR对拮抗剂与CPI-444诱导抗肿瘤反应，并在临床前模型中增强抗PD-（L）1和抗CTLA-4的疗效
3. Immune checkpoint inhibition by anti‐ PDCD PDCD 1 (anti‐ PD PD 1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model [J] . Qiu Yushi, Li Zhimin, Pouzoulet Frederic, British Journal of Haematology . 2018,第4期

机译：免疫检查点抑制抗PDCD PDCD 1（抗PD PD1）单克隆抗体对免疫活性临床前模型中的中枢神经系统淋巴瘤具有显着的治疗活性
4. CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDRl-Resistant Maytansine Payload, Yields Excellent Efficacy and Safety in Preclinical Models [C] . Robyn Μ. Barfield, Penelope Μ. Drake, Adam Carlson, Protein Engineering Summit. . 2018

机译：CAT-02-106，一种耐受MDRL抗性Maytansine有效载荷的位点特异性缀合的抗CD22抗体，在临床前模型产生优异的功效和安全性
5. Generation, characterization and efficacy testing of monoclonal antibodies for immunotherapy of respiratory tularemia. [D] . Roche Pabon, Marly Isabel. 2009

机译：单克隆抗体的制备，鉴定和功效测试
6. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL [O] . Jennifer A. Woyach, Farrukh Awan, Ian W. Flinn, -1

机译：Fc工程CD19抗体XmAb5574（MOR00208）的1期试验证明了CLL复发的安全性和初步疗效
7. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody [O] . Jie Fu, Fang Wang, Li-hou Dong, 2017

机译：JS-001的疗效，药代动力学和免疫原性的临床前评估，一种编程的细胞死亡蛋白-1（PD-1）单克隆抗体

587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models

著录项

引文网络

相似文献

相关主题

期刊订阅